Agenus Inc.

NASDAQ:AGEN

Biotechnology

Healthcare
$6.40 -0.17%

-$0.01 today

Market cap
$289.58M
Beta
1.54
P/E (TTM)
1.7
EPS (TTM)
$1.70
52W Low $2.71High $7.34

Volume 0.88M

Average 0.82M

AGEN Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Agenus Inc.NASDAQ: AGEN

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q1 FY2026 cost of revenue of $583K fell 97.3% year over year, behind the -55.6% change in trailing-twelve-month cost of revenue. Sequentially, it fell 92.2% from the prior quarter. Over 3 fiscal years it compounded at -25.9% a year.

Context

  • Cost of revenue amounted to 70.4% of revenue in FY2025, down 80.4 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -97.3% toward the trailing-twelve-month pace of -55.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$583K-92.2% QoQ
Last fiscal yearDec 2025
$80.36M-48.5% YoY
LTMMar 2026
$59.29M-55.6% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-97.3%——
1 year-48.5%——
3-year CAGR-25.9%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
80.36M USD
Year-over-year change
-48.5%
4-year CAGR
-18.5%

Cost of Revenue vs competitors

How AGEN compares with its peers on the latest reported figures

  • AGEN's LTM Mar 2026 cost of revenue of $59.29M is the highest of the 10 companies compared; the peer median is $711K.
  • Its year-over-year change of -55.6% is the 6th highest of 8, against a peer median of -22.4%.
  • Cost of revenue amounts to 47.9% of revenue for AGEN, versus a peer median of 51.7%.
AGEN Competitors Peer median
Cost of Revenue for AGEN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AGENAgenus Inc.LTM Mar 2026$59.29M -55.6%-25.9%47.9%
FATEFate Therapeutics, Inc.LTM Mar 2026$32.58M -62.0%-2.1%515.8%
SEERSeer, Inc.LTM Mar 2026$7.78M -27.0%-0.2%51.7%
IRDOpus Genetics, Inc.LTM Mar 2026$6.04M -22.4%—50.4%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$2.24M +39.7%——
PLRXPliant Therapeutics, Inc.LTM Mar 2026$711K +14.3%——
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$151K ———
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$46K +4.5%——
TTRXTurn Therapeutics Inc.LTM Mar 2026$42.29K ———
HURATuHURA Biosciences, Inc.LTM Mar 2026$23.47K -63.1%——
Peer median (excluding AGEN) $711K-22.4%-1.2%51.7%

Competitors are the stored peer set for AGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue295.67M98.02M156.31M103.46M114.2M
Cost of Revenue182.08M197.26M237.68M156.01M80.36M
Gross Profit113.59M(99.24M)(81.37M)(52.55M)33.84M
Gross Margin38.4%-101.2%-52.1%-50.8%29.6%
Research & Development178.61M0234.57M155.53M0
Selling, General & Admin76.36M81.01M78.74M71.88M54.39M
Operating Expenses87.84M80.19M78.18M67.92M54.39M
Depreciation & Amortization6.79M6.95M13.59M13.34M10M
EBITDA43.78M(161.85M)(145.92M)(101.3M)62.19M
EBITDA Margin14.8%-165.1%-93.4%-97.9%54.5%
Operating Income25.75M(179.43M)(159.55M)(120.48M)(20.56M)
Operating Margin8.7%-183.0%-102.1%-116.4%-18.0%
Interest Income00000
Interest Expense65.72M61.86M97.93M117.63M55.27M
Other Income / Expenses(54.47M)(51.23M)(97.89M)(111.8M)17.47M
Income Before Tax(28.72M)(230.66M)(257.44M)(232.27M)(3.08M)
Pre-Tax Margin-9.7%-235.3%-164.7%-224.5%-2.7%
Income Tax Expense00000
Net Income(23.93M)(220.07M)(245.76M)(227.21M)115K
Net Margin-8.1%-224.5%-157.2%-219.6%0.1%
EPS (Basic)(2.11)(15.64)(13.75)(10.59)(0.00)
EPS (Diluted)(2.11)(15.64)(13.75)(10.59)(0.00)
Weighted Avg Shares11.45M14.09M17.89M21.47M29.73M
Weighted Avg Shares (Diluted)11.45M14.09M17.89M21.47M29.73M

Agenus Inc.

NASDAQ:AGEN

Intrinsic Alpha fair value

Locked

Current Price

$6.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.